Priority of cystatin C among other renal biomarkers for pre-eclampsia diagnosing

Authors

  • V.G. Marichereda Odessa National Medical University, Odesa, Ukraine
  • M.Yu. Holubenko Odessa National Medical University, Odesa, Ukraine
  • L.I. Berlinska Odessa National Medical University, Odesa, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.9.2.2020.203407

Keywords:

реэклампсия, цистатин С, креатинин, мочевина

Abstract

Background. Placental ischemia and renal dysfunction are crucial elements of pre-eclampsia development. Thorough renal function control enables timely delivery and minimization of complications during pregnancy. It also enables pre-eclampsia diagnosing at the pre-clinical stage. The purpose was to study serum cystatin C levels and to evaluate its efficacy in pre-eclampsia prognosis compared to creatinine and urea serum levels in pregnant patients. Materials and methods. Thirty females at their first trimester of pregnancy were enrolled. Twenty females with a history of pre-eclampsia risk factors were included into the study group, 10 healthy females without any pre-eclampsia risk factors were included into the control group. Serum levels of cystatin C, creatinine and urea were studied at 22–36 weeks of gestation. Results. Comparison of mean values in a group of females, who subsequently developed pre-eclampsia (n = 8), and average values in females without pre-eclampsia (n = 12) demonstrated following cystatin C, creatinine and urea levels: 1.34 ± 0.11 mg/l vs 0.88 ± 0.03 mg/l, a significant difference for cystatin C has been demonstrated С (р < 0.001); 78.54 ± 3.68 μmol/l vs 69.06 ± 4.94 μmol/l, a significant difference for creatinine has been demonstrated (р < 0.05); 2.79 ± 0.34 mmol/l vs 3.07 ± 0.23 mmol/l, no statistically significant difference for urea has been demonstrated (р = 0.364). In a group of pregnant females, who subsequently developed pre-eclampsia, glomerular filtration rate as calculated based on creatinine level (88.25 ± 5.76 ml/min/1.73 m2) was physiologic. However, glomerular filtration rate as calculated based on cystatin C level (58.62 ± 4.11 ml/min/1.73 m2) demonstrated a significant decrease of renal filtration capacity. In females with cystatin C level over 1.0 mg/l (n = 10), sensitivity of 87.5 % and specificity of 100 % regarding pre-eclampsia development has been demonstrated for 1.08 value. Area under the ROС curve analysis demonstrated the difference between these three markers in a group of pregnant females, who further developed pre-eclampsia. Namely, cystatin C level as a perfect marker (0.99), creatinine level as a good marker (0.78) and urea level as a poor marker (0.42) for early pre-eclampsia diagnosing. Conclusions. Our study demonstrated a significant elevation of cystatin C serum levels in pregnant patients at the pre-clinical stage of eclampsia without any increase in creatinine and urea serum levels. Cystatin C serum level is an effective and reliable marker for pre-eclampsia prognosis at second and third trimesters of pregnancy.

Downloads

Download data is not yet available.

References

Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 Suppl 1(Suppl 1):1–33. doi:10.1002/ijgo.12802.

Thomas C, Thomas L. Renal failure--measuring the glomerular filtration rate. Dtsch Arztebl Int. 2009;106(51-52):849–854. doi:10.3238/arztebl.2009.0849.

De Geus HR, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J. 2012;5(2):102–108. doi:10.1093/ckj/sfs008.

Vel'kov VV. Cystatin C and NGAL – the markers of preclinical renal dysfuction and subclinical acute kidney injury. Laboratornaya sluzhba. 2015;4(2):38–43. (in Russian).

Niraula A, Lamsal M, Baral N, et al. Cystatin-C as a Marker for Renal Impairment in Preeclampsia. J Biomark. 2017;2017:7406959. doi:10.1155/2017/7406959.

Dhokikar GD, Ingale P, Birla VH. Cystatin C in pre-eclampsia: a case control study. Int J Curr Res. 2015;7(7):18226–18230.

Padma Y, Aparna VB, Kalpana B, Ritika V, Sudhakar PR. Renal markers in normal and hypertensive disorders of pregnancy in Indian women: a pilot study. Int J Reprod Contracept Obstet Gynecol. 2013;2(4):514–520. doi:10.5455/2320-1770.ijrcog20131205.

Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides KH. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2013;42(6):634–643. doi:10.1002/uog.12494.

Artiomenko VV, Berlinskaya LI. Risk factors of preeclampsia development. Visnyk mors'koi' medycyny. 2018;1(78):108–114. doi:10.5281/zenodo.1240781. (in Ukrainian).

Published

2021-09-08

How to Cite

Marichereda, V., Holubenko, M., & Berlinska, L. (2021). Priority of cystatin C among other renal biomarkers for pre-eclampsia diagnosing. KIDNEYS, 9(2), 87–91. https://doi.org/10.22141/2307-1257.9.2.2020.203407

Issue

Section

Original Articles